Novavax shares rose ahead of Q4 earnings, fuelled by a Pfizer partnership involving a $30 million upfront payment. While analysts like TD Cowen and BofA raised price targets, warnings of a potential 20% crash persist. Activist pressure from Shah Capital remains an overhang, despite expectations for revenue growth and narrowed losses.